In-Office Retail Products
Certified CBD topicals for your practice and retail shelf. No minimum orders.
3 products
No minimum orders · Available in 6 or 12-packs
Why Practitioners Choose Kannaco
Professional Grade. Not Marketing Grade.
Every product in this collection is formulated to meet the standards practitioners demand — not the minimums the market accepts.
100%
Full Transparency
Every batch is independently tested. COAs are available on every product page — potency, purity, and contaminant panels included.
ISO-accredited third-party labs
LegitScript Certified
Kannaco holds LegitScript certification — the highest compliance standard in the CBD industry, required by Google, Facebook, and major payment processors.
Verified compliant merchant
Practitioner Support
Our clinical team provides dosing guidance, patient education materials, and ongoing support so you can recommend with confidence.
Dedicated practitioner success team
Click the 'Apply for Wholesale' button on any collection or product page. You'll complete a short verification form (license type, license number, practice name). Our team reviews applications within 24 hours on business days. Once approved, your account is automatically upgraded to wholesale pricing across all products.
Wholesale accounts require a valid, active professional license in a qualifying discipline.
Start Your Application
Kannaco wholesale accounts are available to licensed practitioners including: Medical Doctors (MD/DO), Chiropractors (DC), Physical Therapists (PT/DPT), Naturopathic Doctors (ND), Registered Nurses and Nurse Practitioners (RN/NP/APRN), Licensed Massage Therapists (LMT), Acupuncturists (LAc), and Sports Medicine Physicians. If your license type is not listed, contact our team — we review all applications individually.
No minimum order quantity is required on your first wholesale purchase — we want you to sample the full range before committing to larger orders. After your first order, a soft MOQ of $150 per order applies to maintain wholesale pricing. There are no subscription commitments or auto-ship requirements.
Every product page includes a direct link to the current batch COA from our ISO-accredited third-party lab. COAs include full cannabinoid potency panels, residual solvent testing, heavy metals, pesticides, and microbial contaminants. If you need COAs for a specific lot number or historical batch, contact your account manager and we'll provide them within one business day.
LegitScript is the highest compliance standard in the CBD and supplement industry. It is required by Google, Meta, and major payment processors to run advertising for CBD products. For practitioners, it means Kannaco has passed rigorous verification of product claims, labeling accuracy, ingredient sourcing, and business practices. Recommending a LegitScript-certified brand protects your practice from liability associated with unverified supplement recommendations.
Yes. Wholesale practitioners receive access to our patient education library, including product comparison sheets, dosing guides, and condition-specific recommendation protocols. These materials are designed to support practitioner-patient conversations and are formatted for in-office distribution. All materials are reviewed by our clinical advisory board and updated quarterly.
Our flagship topicals combine CBD (cannabidiol) with CBG (cannabigerol) in a clinically-informed ratio. CBG acts on CB1 and CB2 receptors with a distinct mechanism from CBD — together they produce what researchers call the 'entourage effect,' where cannabinoids work synergistically for greater efficacy than either compound alone. CBG has demonstrated particular affinity for α2-adrenoceptors, which play a role in pain modulation.
Wholesale orders over $250 ship free via ground (2–5 business days). Expedited shipping (1–2 business days) is available at cost. All orders ship from our fulfillment center in Colorado within 1 business day of order placement. Tracking is provided via email and accessible in your account dashboard. We do not currently ship internationally for wholesale accounts.
Free shipping threshold applies to the post-discount wholesale order total.
No questions in this category yet.
Research & Evidence
The Science Behind the Endocannabinoid System
ECS research spans more than three decades and thousands of peer-reviewed studies. Here are the key milestones that shaped our understanding of this remarkable system — and why it matters for your wellness today.
1988
First Cannabinoid Receptor Discovered
Dr. Allyn Howlett and William Devane identified the first cannabinoid receptor (CB1) in the rat brain, establishing the biological basis for how cannabinoids affect the nervous system.
Source: Howlett et al., Molecular Pharmacology, 1988
1992
Anandamide — The Body's Own Cannabinoid
Researchers at Hebrew University discovered anandamide, the first endocannabinoid — a naturally occurring compound produced by the human body that binds to the same receptors as THC.
Source: Devane et al., Science, 1992
1993
CB2 Receptor Identified
The second major cannabinoid receptor, CB2, was discovered in the immune system. This finding revealed that the ECS plays a significant role in immune regulation and peripheral tissue response.
Source: Munro et al., Nature, 1993
1995
2-AG: The Most Abundant Endocannabinoid
2-arachidonoylglycerol (2-AG) was identified as the most abundant endocannabinoid in the body, with full agonist activity at both CB1 and CB2 receptors — playing a key role in immune and neurological regulation.
Source: Mechoulam et al., Biochemical Pharmacology, 1995
1998
Raphael Mechoulam Names the ECS
The Israeli chemist who first isolated THC in 1964 formally characterized the endocannabinoid system as a unified regulatory network, coining the term and establishing its role in maintaining homeostasis.
Source: Mechoulam & Ben-Shabat, European Journal of Biochemistry, 1999
2003
U.S. Government Patents Cannabinoids as Neuroprotectants
The U.S. Department of Health and Human Services was granted Patent #6,630,507 for cannabinoids as antioxidants and neuroprotectants, acknowledging their therapeutic potential.
Source: U.S. Patent 6,630,507, 2003
2009
ECS Receptors Found in Human Skin
Researchers confirmed the presence of both CB1 and CB2 receptors throughout human skin — in keratinocytes, hair follicles, sebaceous glands, and sensory nerve fibers — validating the mechanism for topical cannabinoid activity.
Source: Bíró et al., Trends in Pharmacological Sciences, 2009
2014
Clinical Endocannabinoid Deficiency Recognized
Dr. Ethan Russo proposed and documented Clinical Endocannabinoid Deficiency (CECD) as a condition where insufficient ECS tone may contribute to chronic discomfort, sleep disruption, and mood challenges.
Source: Russo, Cannabis and Cannabinoid Research, 201635+
Years of Peer-Reviewed ECS Research
20,000+
Published Studies on Cannabinoids
100+
Known Phytocannabinoids in Hemp
2
Primary ECS Receptor Types Identified